BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
I'm PortAI, I can summarize articles.
BridgeBio Pharma Inc. announced that the FDA has approved Attruby (acoramidis) for treating adults with Transthyretin amyloid cardiomyopathy (ATTR-CM). This drug aims to reduce cardiovascular death and related hospitalizations. The approval follows positive results from the ATTRibute-CM Phase 3 study. BridgeBio will receive a payment under a royalty funding agreement and has submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025. Bayer has exclusive rights to commercialize acoramidis in Europe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments